Open access
Sep 2026
Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.
Immune checkpoint inhibitors (ICIs) have transformed Merkel cell carcinoma (MCC) outcomes, but most patients with MCC develop resistance. We identified T cell receptor (TCR)MCC1, a highly avid, HLA-A*02:01-restricted TCR targeting the Merkel cell polyomavirus (MCPyV) oncoprotein large-T antigen15-23. Seven patients wit...
Yuta Asano, Joshua R. Veatch, Cheng-Jung Sung et al.
· Science Translational Medici... · 0 citations